Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HROW
SELLHarrow, Inc. · Healthcare · United States · $1.5B · Avg Vol: $27M/d
COMPANY DESCRIPTION
Harrow, Inc. is an ophthalmic pharmaceutical company focused on the development, production, and commercialization of a broad portfolio of branded and generic eye care products. The company leverages its vertically integrated capabilities, including sterile ophthalmic compounding, and an expanding commercial infrastructure to serve the specialized needs of the ophthalmic market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88.6M | 130.2M | 199.6M | 272.3M | 45.4% | 268.7M | 348.5M | 517.5M | 37.9% |
| EPS | -0.51 | -0.75 | -0.49 | -0.14 | — | -0.36 | — | — | — |
| Shares | 29.9M | 35.2M | 35.6M | 37.2M | +24.5% | 37.3M | — | — | — |
| Debt | 112.2M | 193.2M | 228.8M | 252.0M | 30.9% | 300.7M | — | — | — |
| Equity | 27.6M | 70.8M | 69.7M | 52.4M | 23.9% | — | — | — | — |
| Op CF | 1.7M | 3.8M | -22.2M | 43.9M | 195.2% | 15.2M | — | — | — |
| Inv CF | -1.7M | -152.6M | -33.2M | -5.5M | — | — | — | — | — |
| Fin CF | 54.1M | 126.5M | 28.5M | -12.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HROW are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HROW | Harrow, Inc.(you) | $1.5B | 35 | SELL |
| GLAS | Glass House Brands Inc. | $899M | 35 | HOLD |
| AMLX | Amylyx Pharmaceuticals, Inc. | $2.0B | 28 | SELL |
| BIOA | BioAge Labs, Inc. | $968M | 31 | SELL |
| ESPR | Esperion Therapeutics, Inc. | $817M | 33 | SELL |
| VREO.CN | Vireo Growth Inc. | $500M | 36 | HOLD |
| XERS | Xeris Biopharma Holdings, Inc. | $1.4B | 58 | HOLD |
| CURA.TO | Curaleaf Holdings, Inc. | $2.5B | 51 | HOLD |
| EOLS | Evolus, Inc. | $394M | 39 | HOLD |
| HIMS | Hims & Hers Health, Inc. | $6.5B | 32 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%